OneSource Specialty Pharma has entered into a strategic manufacturing partnership with Formycon AG (Formycon), an independent biosimilar developer headquartered in Munich, for biosimilars. Under the partnership, the company will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics’ facility in Bangalore. The collaboration brings together Formycon’s Biosimilar development excellence with the company’s end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.
The partnership reflects the shared commitment of both companies to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires not only scientific excellence but also a sustainable, cost-effective manufacturing model - that the company is specifically positioned to deliver.
Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. The company complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1977.20 |
| Dr. Reddys Labs. | 1135.65 |
| Cipla | 1444.65 |
| Lupin | 2394.70 |
| Zydus Lifesciences | 1099.60 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: